Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms The RIFF study
- Sponsors Chugai Pharmaceutical; Roche
- 19 May 2021 Results of pooled analysis CAPACITY studies (NCT00287729 and NCT00287716), and from all patients in GIPF-001 (NCT00047645) and RIFF (Cohort A) (NCT01872689) assessing change in the DLco measurements over 6-month intervals, presented at the 117th International Conference of the American Thoracic Society.
- 02 Oct 2020 Results published in the European Respiratory Journal
- 20 May 2020 Results of post-hoc exploratory analyses evaluating the associations for imaging features with baseline FVCpp and biomarker levels from CAPACITY-006 (NCT00287729) and RIFF (NCT01872689), presented at the 116th International Conference of the American Thoracic Society.